U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10571882
Filing Date		2006-12-12
First Named Inventor	Barne	ett
Art Unit		1648
Examiner Name	Hump	phrey
Attorney Docket Number		032441.00141

				U.S.I	PATENTS	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5840313		1998-11-24	Vahlne et al	
	2	5846546		1998-12-08	Hurwitz et al	
	3	5876731		1999-03-02	Sia et al	
	4	6602705		2003-08-05	Barnett et al	
	5	6689879		2004-02-10	Barnett et al	
	6	7211659		2007-05-01	Zur Megede et al.	
If you wisl	n to add	additional U.S. Pater	t citatio	n information pl	lease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10571882		
Filing Date		2006-12-12		
First Named Inventor	Barne	att		
Art Unit		1648		
Examiner Name	Humphrey			
Attorney Docket Number		032441.00141		

	1									
If you wish	n to ac	dd additional U.S. Pub	lished Ap	plication cita	tion	information p	lease click the Add	butto	ın.	
				FOREIGN P	ATE	NT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i			Publication Date	Name of Patentee Applicant of cited Document	or	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
	1	03020876	wo		2	2003-03-13	Chiron Corp.			
	2	03038057	wo		2	2003-05-08	Genphar, Inc.			
	3	03077859	wo		2	2003-09-25	Merck & Co, Inc.			
	4	0203917	wo		2	2002-01-17	Alphavax Inc; Unive of North Carolina	rsity		
	5	0181609	wo		2	2001-11-01	Chiron Corp.			
	6	0376598	wo		2	2003-09-18	Merck & Co, Inc.			
	7	9834640	wo		1	1998-08-13	Merck & Co, Inc.			
	8	0039302	wo		2	2000-07-06	Chiron Corp.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10571882		
Filing Date		2006-12-12		
First Named Inventor	Barne	tt		
Art Unit		1648		
Examiner Name	Humphrey			
Attorney Docket Number		032441.00141		

	9	0039303	wo		2000-07-06	Chiron Corp.			
	10	0039304	wo		2000-07-06	Chiron Corp.			
	11	0204493	wo		2002-01-17	Chiron Corp.			
If you wisl	h to ac	dd additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	า		
			NON-PATEN	NT LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when approp late, pages(s), volume-is		T5	
	1	Amara et al., "Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine," J Virol. 2002 Jun;76(12):6138-46.							
	2	André et al., "Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage," J Virol. 1998 Feb;72(2):1497-503.							
	3	Barnett et al., "The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region," J Virol. 2001 Jun;75(12):5526-40.							
	4	Buge et al., "An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge," J Virol. 1997 Nov;71 (11):8531-41.							
	5	Chakrabarti et al., "Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization," J Virol. 2002 Jun;76(11):5357-68.							
	6	Yang et al., "Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin," J Virol. 2002 May,76(9):4634-42.							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10571882		
Filing Date		2006-12-12		
First Named Inventor	Barne	Barnett		
Art Unit		1648		
Examiner Name	Humphrey			
Attorney Docket Number		032441.00141		

	7		et al., "Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble zed envelope glycoprotein trimers," J Virol. 2001 Feb;75(3):1165-71.					
	8		egede et al., "Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 pe B pol and gagpol DNA vaccines," J Virol. 2003 Jun;77(11):6197-207.					
If you wis	h to a	dd add	ditional non-patent literature document citation information p	lease click the Add b	outton			
			EXAMINER SIGNATURE					
Examiner Signature Date Considered		•						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.